Accéder au contenu
Merck

FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity.

Cell metabolism (2023-04-20)
Nicolas Wieder, Juliana Coraor Fried, Choah Kim, Eriene-Heidi Sidhom, Matthew R Brown, Jamie L Marshall, Carlos Arevalo, Moran Dvela-Levitt, Maria Kost-Alimova, Jonas Sieber, Katlyn R Gabriel, Julian Pacheco, Clary Clish, Hamdah Shafqat Abbasi, Shantanu Singh, Justine C Rutter, Martine Therrien, Haejin Yoon, Zon Weng Lai, Aaron Baublis, Renuka Subramanian, Ranjan Devkota, Jonnell Small, Vedagopuram Sreekanth, Myeonghoon Han, Donghyun Lim, Anne E Carpenter, Jason Flannick, Hilary Finucane, Marcia C Haigis, Melina Claussnitzer, Eric Sheu, Beth Stevens, Bridget K Wagner, Amit Choudhary, Jillian L Shaw, Juan Lorenzo Pablo, Anna Greka
RÉSUMÉ

Cellular exposure to free fatty acids (FFAs) is implicated in the pathogenesis of obesity-associated diseases. However, there are no scalable approaches to comprehensively assess the diverse FFAs circulating in human plasma. Furthermore, assessing how FFA-mediated processes interact with genetic risk for disease remains elusive. Here, we report the design and implementation of fatty acid library for comprehensive ontologies (FALCON), an unbiased, scalable, and multimodal interrogation of 61 structurally diverse FFAs. We identified a subset of lipotoxic monounsaturated fatty acids associated with decreased membrane fluidity. Furthermore, we prioritized genes that reflect the combined effects of harmful FFA exposure and genetic risk for type 2 diabetes (T2D). We found that c-MAF-inducing protein (CMIP) protects cells from FFA exposure by modulating Akt signaling. In sum, FALCON empowers the study of fundamental FFA biology and offers an integrative approach to identify much needed targets for diverse diseases associated with disordered FFA metabolism.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Cocktails d′inhibiteurs de protéases cOmplete ULTRA, sans EDTA, pastilles EASYpack, Tablets supplied in foil blister packs.
Sigma-Aldrich
Thapsigargine, ≥98% (HPLC), solid film
Sigma-Aldrich
Rapamycine, Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus
Sigma-Aldrich
Bafilomycin A1 Ready Made Solution, 0.16 mM in DMSO, from Streptomyces griseus
Sigma-Aldrich
TGF-β RI Kinase Inhibitor II, TGF-β RI Kinase Inhibitor II, CAS 446859-33-2, is a cell-permeable, potent, reversible, ATP-competitive inhibitor of TGF-β R1 kinase (IC₅₀ = 23 nM and 4 nM for ALK5 binding & auto-phosphorylation).